Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02933879 · ClinicalTrials.gov registry record · Phase 2

Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study

A Phase 2 study, sponsored by Sun Pharmaceutical Industries.

Completed
Registry status
Phase 2
Development phase
184
Enrollment target

NCT02933879 is a Phase 2 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 184 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02933879, a Phase 2 study, has completed, sponsored by Sun Pharmaceutical Industries.

COMPLETED
Registry status
Phase 2
Development phase
184 participants
Enrollment target

Study Summary

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8-Week Regimens of NVXT topical product in Patients with Mild to Moderate Onychomycosis

Interventions

  • DRUG NVXT topical
  • DRUG Placebo (Vehicle) Topical

Trial Details

FieldValue
Enrollment Target 184 participants
Start Date 2016-03-21
Est. Completion 2018-06-21
Phase Phase 2

Sponsor

Sun Pharmaceutical Industries

48 total trials

What the Registry Record Tells You About NCT02933879

The ClinicalTrials.gov registry entry for NCT02933879 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which NVXT topical is the first listed.

NCT02933879 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02933879 about?

NCT02933879 is a clinical study titled "Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study". A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8-Week Regimens of NVXT topical product in Patients with Mild to Moderate Onychomycosis

What is the current status of trial NCT02933879?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2016-03-21. Estimated completion is 2018-06-21.

What interventions are being tested in trial NCT02933879?

The interventions under investigation include: NVXT topical (DRUG), Placebo (Vehicle) Topical (DRUG).

Who is sponsoring clinical trial NCT02933879?

This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.